Great West Life Assurance Co. Can Sells 806 Shares of American National Insurance (ANAT)

Great West Life Assurance Co. Can decreased its position in American National Insurance (NASDAQ:ANAT) by 42.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,110 shares of the insurance provider’s stock after selling 806 shares during the period. Great West Life Assurance Co. Can’s holdings in American National Insurance were worth $130,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its holdings in American National Insurance by 7.7% in the first quarter. BlackRock Inc. now owns 347,522 shares of the insurance provider’s stock valued at $40,644,000 after buying an additional 24,883 shares during the period. Aperio Group LLC lifted its holdings in American National Insurance by 15.1% in the first quarter. Aperio Group LLC now owns 247,405 shares of the insurance provider’s stock valued at $28,936,000 after buying an additional 32,366 shares during the period. Northern Trust Corp lifted its holdings in American National Insurance by 0.9% in the first quarter. Northern Trust Corp now owns 97,540 shares of the insurance provider’s stock valued at $11,409,000 after buying an additional 915 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in American National Insurance by 43.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 91,550 shares of the insurance provider’s stock valued at $10,708,000 after buying an additional 27,803 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in American National Insurance by 4.3% in the fourth quarter. Bank of New York Mellon Corp now owns 70,604 shares of the insurance provider’s stock valued at $9,055,000 after buying an additional 2,912 shares during the period. Institutional investors and hedge funds own 64.85% of the company’s stock.

Get American National Insurance alerts:

In related news, Director Arthur Oleen Dummer purchased 537 shares of the firm’s stock in a transaction on Friday, May 18th. The stock was purchased at an average cost of $121.44 per share, with a total value of $65,213.28. Following the completion of the purchase, the director now owns 6,324 shares in the company, valued at approximately $767,986.56. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider E Douglas Mcleod purchased 1,000 shares of the firm’s stock in a transaction on Wednesday, May 30th. The stock was bought at an average cost of $119.01 per share, with a total value of $119,010.00. Following the completion of the purchase, the insider now owns 20,750 shares of the company’s stock, valued at approximately $2,469,457.50. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 1,877 shares of company stock valued at $224,724. Insiders own 23.52% of the company’s stock.

American National Insurance opened at $121.78 on Friday, MarketBeat reports. The firm has a market capitalization of $3.24 billion, a P/E ratio of 17.17 and a beta of 1.15. American National Insurance has a 12-month low of $110.43 and a 12-month high of $134.03.

American National Insurance (NASDAQ:ANAT) last posted its quarterly earnings results on Tuesday, April 24th. The insurance provider reported $1.63 earnings per share for the quarter. American National Insurance had a net margin of 13.76% and a return on equity of 3.76%. The firm had revenue of $803.38 million during the quarter.

The business also recently declared a quarterly dividend, which was paid on Friday, June 15th. Shareholders of record on Friday, June 1st were paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.69%. The ex-dividend date of this dividend was Wednesday, May 30th.

Several research firms recently issued reports on ANAT. ValuEngine upgraded shares of American National Insurance from a “hold” rating to a “buy” rating in a report on Wednesday, March 7th. BidaskClub lowered shares of American National Insurance from a “hold” rating to a “sell” rating in a report on Thursday, May 31st.

About American National Insurance

American National Insurance Company, together with its subsidiaries, provides various insurance products and services in the United States, the District of Columbia, and Puerto Rico. The company's Life segment offers whole life, term life, universal life, variable universal life, and credit life insurance products.

Hologic, Inc. (HOLX) Shares Sold by Sciencast Management LP

Sciencast Management LP lowered its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 37.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,668 shares of the medical equipment provider’s stock after selling 5,090 shares during the quarter. Sciencast Management LP’s holdings in Hologic were worth $335,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Hologic during the 1st quarter valued at about $146,000. Synovus Financial Corp acquired a new position in Hologic during the 1st quarter valued at about $164,000. Homrich & Berg acquired a new position in Hologic during the 4th quarter valued at about $219,000. IBM Retirement Fund acquired a new position in Hologic during the 1st quarter valued at about $227,000. Finally, Cambridge Investment Research Advisors Inc. acquired a new position in Hologic during the 4th quarter valued at about $235,000. 93.33% of the stock is currently owned by hedge funds and other institutional investors.

Get Hologic alerts:

In related news, insider Peter J. Valenti III sold 10,107 shares of the stock in a transaction that occurred on Tuesday, May 29th. The stock was sold at an average price of $38.52, for a total transaction of $389,321.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Karleen Marie Oberton sold 12,196 shares of the stock in a transaction that occurred on Wednesday, May 2nd. The stock was sold at an average price of $40.00, for a total value of $487,840.00. Following the sale, the vice president now directly owns 13,825 shares of the company’s stock, valued at $553,000. The disclosure for this sale can be found here. 0.88% of the stock is currently owned by corporate insiders.

Shares of NASDAQ:HOLX opened at $40.24 on Tuesday. The company has a market capitalization of $11.04 billion, a P/E ratio of 19.82, a PEG ratio of 1.91 and a beta of 0.86. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.98 and a current ratio of 1.26. Hologic, Inc. has a fifty-two week low of $35.10 and a fifty-two week high of $46.80.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.53 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.53. Hologic had a negative net margin of 4.15% and a positive return on equity of 20.86%. The business had revenue of $789.30 million for the quarter, compared to the consensus estimate of $781.23 million. During the same period last year, the company posted $0.50 EPS. Hologic’s revenue for the quarter was up 10.3% on a year-over-year basis. analysts forecast that Hologic, Inc. will post 2.23 EPS for the current fiscal year.

A number of research firms have issued reports on HOLX. Leerink Swann downgraded shares of Hologic from an “outperform” rating to a “market perform” rating and cut their target price for the company from $48.00 to $41.00 in a research report on Thursday, May 3rd. BTIG Research restated a “buy” rating and set a $44.00 target price on shares of Hologic in a research report on Sunday, May 6th. Zacks Investment Research downgraded shares of Hologic from a “hold” rating to a “sell” rating in a research report on Monday, April 30th. BidaskClub upgraded shares of Hologic from a “sell” rating to a “hold” rating in a research report on Friday, April 27th. Finally, TheStreet downgraded shares of Hologic from a “b-” rating to a “c-” rating in a research report on Wednesday, May 2nd. Two analysts have rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating to the company’s stock. Hologic currently has a consensus rating of “Hold” and an average target price of $44.87.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.